In C666/C666-CD137 tumor-bearing, humanized mice, analysis of splenic CD8+ T cells revealed that rhCD137L-MSNs modestly enhanced the expression of granzyme B, while marginally reducing the levels of OX40, HLA-DR, TRAIL and FasL, compared to other treatment groups (Figure S9E). This evidence concerns the gene FASLG and neoplasm.